All 1 tracked stories fall under one category: market-trends. Aeterna Zentaris GmbH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zentaris IVF GmbH
All 1 tracked stories fall under one category: market-trends. Aeterna Zentaris GmbH is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.6 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention Zentaris IVF GmbH, all published on March 6, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zentaris IVF GmbH. Shared-story counts are live from our verified record — not editorial picks.
COSCIENS Biopharma Inc. (TSX: CSCI) has announced a strategic cessation of funding for its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH, effectively triggering an insolvency process. This decision follows a critical failure in the Phase 3 DETECT trial for Macrilen’s pediatric indication and a subsequent setback in FDA negotiations.